Vaxcyte, Inc. disclosed that it completed a large equity financing following the sale of 11.0 million shares at $50.00 per share, with underwriters exercising their option to purchase an additional 1.65 million shares. The offering generated approximately $600.2 million in net proceeds after underwriting discounts and expenses. The shares were sold pursuant to an effective Form S-3 registration statement, and the transaction closed on February 2, 2026.